Overview
Clinical Meaning
ARDS is characterized by diffuse alveolar damage from pulmonary or extrapulmonary insults.
AGPCNP
AGPCNP
ARDS is characterized by diffuse alveolar damage from pulmonary or extrapulmonary insults. The exudative phase (days 1-7) involves damage to the alveolar-capillary membrane: type I pneumocyte injury allows protein-rich edema fluid to flood alveoli, forming hyaline membranes. Neutrophil-mediated inflammation releases proteases and reactive oxygen species, amplifying damage. Surfactant dysfunction increases surface tension, promoting alveolar collapse. The result is bilateral pulmonary infiltrates, severe hypoxemia refractory to supplemental oxygen, and reduced lung compliance. Berlin criteria classify severity by PaO2/FiO2 ratio on PEEP >= 5: mild (200-300), moderate (100-200), severe (< 100). Lung-protective ventilation targeting low tidal volumes (6 mL/kg IBW) reduces ventilator-induced lung injury (VILI) from overdistention (volutrauma), cyclic opening/closing of atelectatic alveoli (atelectrauma), and biotrauma (cytokine release). The ARDS Network trial demonstrated a 22% mortality reduction with low Vt strategy.
Unlock full lesson + practice questions
4 more sections with scenarios, priorities, and review drills.
Final rapid review before practice
Next study step
Finish the lesson first, then choose a focused activity to apply what you just reviewed.
Continue studying
Sign in to save progress on this lesson.
Unlock the interactive lesson quiz with a plan that includes this AGPCNP pathway. You can still explore topic-filtered questions from the bank hubs below.